Naschitz Brandes Amir represented Rafa Laboratories, a leading Israeli pharmaceutical company, on its initial public offering and secondary offering, with an aggregate value of NIS 600 million.
The Naschitz Brandes Amir Capital Markets team advising Rafa included partners and Co-Heads of Capital Markets (Israel) Dr. Eyal Geva and Roi Turgheman, partner Shachar Hananel, and associate Dor Ofek.